Sudarshan Pharma Industries Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Following its successful public offering, Sudarshan Pharma Industries Limited's made its market debut on Mar 20, 2023 and is now actively traded on the BSEplatform. The IPO mobilized 68,62,400 Shares in total capital, including 68,62,400 Shares in primary equity infusion.
The offering was structured with a price band of ₹71 to ₹73 and minimum investment lots of 1600 shares. Investor participation during the subscription window from Mar 09, 2023 to Mar 14, 2023 demonstrated market confidence in the company's prospects.
The allotment process concluded on Mar 18, 2023, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2008, Sudarshan Pharma Industries Limited (SPIL) is a Mumbai-based company engaged in contract manufacturing, import, export, and supply of specialty chemicals, Active Pharmaceutical Ingredients (APIs), and intermediates. The company sources and supplies generic formulations by outsourcing manufacturing facilities from domestic and international suppliers based on client requirements. Its products find applications across industries such as pharmaceuticals, paints, food, and adhesives. SPIL also supplies medicines and pharma formulations to hospitals, NGOs, government bodies, and healthcare institutions under its own brand, offering around 50 formulations in tablets, capsules, ointments, and injectables. With a strong sales and distribution network across five states, the company markets its products ethically in both Indian and international markets, while also offering formulation development, quality control, and customized pharma solutions.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Customer-focused, order-driven model.
- Wide product portfolio.
- Contract manufacturing capabilities.
- Strong distribution & sales network.
- Diversified operations.
NA
- Mr. Hemal Vasantrai Mehta
- Mr. Sachin Vasantrai Mehta
Sudarshan Pharma Industries Limited
Kfin Technologies Limited